Tekla Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Tekla Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-67,065	Closed	-$2.69M	–	179
2023 Q1	$2.69M	Hold	67,065	–	–	0.1%	108
2022 Q4	$3.11M	Hold	67,065	–	–	0.12%	97
2022 Q3	$2.78M	Buy	67,065 +22,700	+51%	+$1.17M	0.11%	102
2022 Q2	$2.65M	Sell	44,365 -96,361	-68%	-$5.93M	0.1%	107
2022 Q1	$10.2M	Hold	140,726	–	–	0.36%	60
2021 Q4	$11.8M	Hold	140,726	–	–	0.38%	61
2021 Q3	$12.7M	Buy	140,726 +6,136	+5%	+$555K	0.41%	58
2021 Q2	$12.8M	Buy	134,590 +37,110	+38%	+$3.87M	0.42%	61
2021 Q1	$11.1M	Hold	97,480	–	–	0.38%	69
2020 Q4	$13.5M	Hold	97,480	–	–	0.47%	61
2020 Q3	$8.01M	Hold	97,480	–	–	0.3%	77
2020 Q2	$7.63M	Hold	97,480	–	–	0.29%	74
2020 Q1	$4.33M	Hold	97,480	–	–	0.2%	95
2019 Q4	$4.16M	Hold	97,480	–	–	0.16%	121
2019 Q3	$4.17M	Buy	97,480 +59,000	+153%	+$3.21M	0.18%	93
2019 Q2	$2.44M	Sell	38,480 -38,478	-50%	-$2.45M	0.1%	125
2019 Q1	$5.34M	Hold	76,958	–	–	0.22%	92
2018 Q4	$3.35M	Hold	76,958	–	–	0.14%	104
2018 Q3	$5.88M	Hold	76,958	–	–	0.21%	86
2018 Q2	$5.92M	Sell	76,958 -71,600	-48%	-$4.62M	0.22%	88
2018 Q1	$7.58M	Hold	148,558	–	–	0.29%	75
2017 Q4	$6.89M	Hold	148,558	–	–	0.27%	71
2017 Q3	$7.91M	Buy	148,558 +21,250	+17%	+$1.26M	0.28%	66
2017 Q2	$7.91M	Buy	127,308 +38,908	+44%	+$2.34M	0.29%	66
2017 Q1	$5.99M	Hold	88,400	–	–	0.23%	80
2016 Q4	$6.21M	Hold	88,400	–	–	0.26%	70
2016 Q3	$6.27M	Hold	88,400	–	–	0.24%	77
2016 Q2	$4.32M	Hold	88,400	–	–	0.18%	96
2016 Q1	$5.6M	Hold	88,400	–	–	0.24%	81
2015 Q4	$9.92M	Hold	88,400	–	–	0.36%	60
2015 Q3	$8.51M	Buy	88,400 +28,400	+47%	+$3.25M	0.31%	77
2015 Q2	$6.14M	Buy	+60,000	New	+$4.66M	0.22%	77

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Tekla Capital Management's RARE Position: Q2 2023 in Review

Tekla Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2023, closing a stake of 67,065 shares — an estimated $2.69M sold.

Tekla Capital Management first reported a position in RARE in Q2 2015 and held it in 32 quarters. The position peaked at $13.5M in Q4 2020. 243 funds tracked by Wall St. Rank hold RARE as of Q2 2023.

Tekla Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2023 after selling out during the quarter.
Tekla Capital Management sold 67,065 Ultragenyx Pharmaceutical shares in Q2 2023, an estimated $2.69M.
Tekla Capital Management first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and held it in 32 quarters.
Tekla Capital Management's Ultragenyx Pharmaceutical position peaked at $13.5M in Q4 2020.
243 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.